x
Oxford-Harrington Rare Disease Centre operates a transatlantic model that embeds industry expertise directly into academic rare disease programs. The partnership between University of Oxford and
Pennsylvania biotech Ocugen advances a modifier gene therapy approach that resets retinal cellular networks rather than replacing individual mutations, positioning OCU400 to address up to
Founded just three months ago in August 2025, London-based Kindling Bio is inverting the standard adult-to-child drug translation model by developing a gene therapy platform
Norwegian Biotech Secures FDA IND Clearance for Novel Mechanism in Brain Cancer Norwegian biotech Hemispherian brings a distinctive approach to glioblastoma treatment with GLIX1, a
New Jersey biotech Citius Pharmaceuticals is transitioning from a development-stage company to revenue generation as it prepares to commercially launch LYMPHIR™, the only FDA-approved IL-2R-targeted
Swedish biotech VERIGRAFT outlines how it solved regenerative medicine’s manufacturing paradox, creating the first tissue therapy platform designed for industrial-scale production while maintaining patient personalisation.
